Form 4: uniQure CMO Boosts Stake with New Equity Grants

uniQure's Chief Medical Officer, Walid Abi-Saab, received significant grants of restricted stock units and stock options, increasing his beneficial ownership.

Summary

• Walid Abi-Saab, Chief Medical Officer of uniQure N.V., was granted 41,700 Restricted Share Units (RSUs) on March 4, 2026, at a price of $0 per share.
• These RSUs vest in equal annual installments of 1/3 each, starting on the first anniversary of the grant date, contingent on continued employment.
• Concurrently, 808 Ordinary Shares were sold at a weighted average price of $9.06 (ranging from $9.00 to $9.22) to cover estimated withholding taxes upon RSU vesting, not as a discretionary trade.
• Abi-Saab also received a grant of 67,200 Stock Options (Right to Buy) on March 4, 2026, with an exercise price of $9.04.
• The stock options vest 25% on the first anniversary of the grant date, and 6.25% quarterly thereafter until fully vested, subject to continued employment.
• Following these transactions, Abi-Saab beneficially owns 189,669 Ordinary Shares directly and 67,200 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine, positive development for executive alignment, reflecting ongoing compensation practices rather than a specific operational or financial event. The increase in beneficial ownership through equity grants is generally seen as a positive for aligning management and shareholder interests.

Positives

• The Chief Medical Officer received a substantial grant of 41,700 Restricted Share Units, increasing his equity stake in the company.
• An additional grant of 67,200 Stock Options further aligns the executive's long-term interests with shareholder value.
• The sale of 808 shares was non-discretionary and solely for covering estimated withholding taxes, indicating a routine compensation event rather than a divestment.

Negatives

• A small number of shares (808) were sold, though this was a non-discretionary sale to cover tax obligations related to RSU vesting.

Future Outlook

The grants of Restricted Share Units and Stock Options are subject to future vesting schedules, with RSUs vesting in equal annual installments over three years and stock options vesting 25% on the first anniversary and quarterly thereafter, contingent on the Chief Medical Officer's continued employment.

Management Comments

• The Restricted Share Units represent the contingent right to receive one Ordinary Share, vesting in equal annual installments of 1/3 each, beginning on the first anniversary of the grant date, subject to continued employment.
• The sale of 808 shares was executed upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions, and was not a discretionary trade by the Reporting Person.
• The Stock Options vest 25% on the first anniversary of the grant date, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates.

Industry Context

StockSavvy.ai notes that the equity grants to uniQure's Chief Medical Officer are consistent with common executive compensation practices in the biotechnology sector, where long-term incentives like RSUs and stock options are used to align management interests with shareholder value creation and retain key talent.

Stakeholder Impact

• Shareholders: Increased alignment of the Chief Medical Officer's financial interests with the long-term performance of the company, potentially fostering greater commitment to shareholder value creation.
• Employees: Reflects standard executive compensation practices, which can influence overall compensation strategies and morale within the company.

Next Steps

• The Restricted Share Units will begin vesting in equal annual installments of 1/3 each, starting on the first anniversary of the grant date (March 4, 2027).
• The Stock Options will begin vesting 25% on the first anniversary of the grant date (March 4, 2027), with subsequent quarterly vesting of 6.25%.

Key Dates

Keywords

uniQure N.V., QURE, Walid Abi-Saab, Chief Medical Officer, Restricted Share Units, RSUs, Stock Options, Equity Compensation, Insider Transaction, Form 4, Beneficial Ownership